Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy.
Tichy E, Torres A, Bassetti M, Kongnakorn T, Di Virgilio R, Irani P, Charbonneau C. Tichy E, et al. Among authors: charbonneau c. Clin Ther. 2020 May;42(5):802-817. doi: 10.1016/j.clinthera.2020.03.014. Epub 2020 Apr 27. Clin Ther. 2020. PMID: 32349879 Free article. Clinical Trial.
Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
Kongnakorn T, Eckmann C, Bassetti M, Tichy E, Di Virgilio R, Baillon-Plot N, Charbonneau C. Kongnakorn T, et al. Among authors: charbonneau c. Antimicrob Resist Infect Control. 2019 Dec 21;8:204. doi: 10.1186/s13756-019-0652-x. eCollection 2019. Antimicrob Resist Infect Control. 2019. PMID: 31890160 Free PMC article.
Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System.
Torres A, Soriano A, Rivolo S, Remak E, Peral C, Kantecki M, Ansari W, Charbonneau C, Hammond J, Grau S, Wilcox M. Torres A, et al. Among authors: charbonneau c. Clinicoecon Outcomes Res. 2022 Mar 18;14:149-161. doi: 10.2147/CEOR.S329494. eCollection 2022. Clinicoecon Outcomes Res. 2022. PMID: 35330907 Free PMC article.
Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.
Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade C, Charbonneau C, Weinstein D, Kantecki M, Schlamm H, Maertens J. Barnes R, et al. Among authors: charbonneau c. Clin Ther. 2015 Jun 1;37(6):1317-1328.e2. doi: 10.1016/j.clinthera.2015.03.021. Epub 2015 Apr 17. Clin Ther. 2015. PMID: 25891805 Free article.
Nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus treated with linezolid or vancomycin: A secondary economic analysis of resource use from a Spanish perspective.
Rello J, Nieto M, Solé-Violán J, Wan Y, Gao X, Solem CT, De Salas-Cansado M, Mesa F, Charbonneau C, Chastre J. Rello J, et al. Among authors: charbonneau c. Med Intensiva. 2016 Nov;40(8):474-482. doi: 10.1016/j.medin.2016.01.007. Epub 2016 Apr 6. Med Intensiva. 2016. PMID: 27061776 Free article. English, Spanish.
Treatment of immunocompromised patients with suspected invasive fungal infections: economic analysis of diagnostic-driven versus empirical strategies in Algeria and Egypt.
Kaci Z, Shalaby L, Kamal S, Boudjerra N, Gao X, Xue M, Ait Belkacem S, Gab Allah Ibrahim A, Kotb R, Charbonneau C. Kaci Z, et al. Among authors: charbonneau c. Expert Rev Pharmacoecon Outcomes Res. 2019 Dec;19(6):693-700. doi: 10.1080/14737167.2019.1604225. Epub 2019 May 6. Expert Rev Pharmacoecon Outcomes Res. 2019. PMID: 31055986
Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model.
Gordon J, Darlington O, McEwan P, Lumley M, Taie A, Hicks M, Charbonneau C, Blake A, Hawkins N, Goldenberg S, Otter J, Wilcox M. Gordon J, et al. Among authors: charbonneau c. Pharmacoeconomics. 2020 Aug;38(8):857-869. doi: 10.1007/s40273-020-00906-6. Pharmacoeconomics. 2020. PMID: 32249396 Free article.
128 results